Osmotica Pharmaceuticals plc reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 2.2 million compared to USD 25.75 million a year ago. Net loss was USD 17.86 million compared to USD 8.63 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to basic earnings per share from continuing operations of USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.42 compared to diluted earnings per share from continuing operations of USD 0.03 a year ago. Basic loss per share was USD 0.28 compared to USD 0.14 a year ago. Diluted loss per share was USD 0.28 compared to USD 0.14 a year ago. For the nine months, revenue was USD 14.64 million compared to USD 26.63 million a year ago. Net loss was USD 45.2 million compared to USD 24.72 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 0.62 a year ago. Diluted loss per share from continuing operations was USD 1.01 compared to USD 0.62 a year ago. Basic loss per share was USD 0.72 compared to USD 0.41 a year ago. Diluted loss per share was USD 0.72 compared to USD 0.41 a year ago.